BACKGROUND: Despite proven efficacy and increased availability of therapeutic plasma exchange (TPE), mortality for patients with thrombotic thrombocytopenic purpura (TTP) remains high with a limited understanding of those at highest risk of death. STUDY DESIGN AND METHODS: This study utilized the Nationwide Inpatient Sample (2007-2012) to derive a prognostic score for mortality in hospitalized TTP patients. Odds ratios of death with various putative risk factors adjusted for age, sex, and race were calculated (adjOR). Weighted mean of adjOR estimates were incorporated in a risk-stratified score. RESULTS: Among 8203 hospitalizations with TTP as primary admission diagnosis who underwent TPE, 613 deaths were identified (all-cause mortality, 7.5%; median time-to-death, 9 days; interquartile range, 4-14 days). In multivariable logistic regression, arterial thrombosis (adjOR 6.7, 95% confidence interval [CI], 1.1-40.9), intracranial hemorrhage (adjOR, 6.1; 95% CI, 1.6-23.2), age at least 60 years (adjOR, 3.5; 95% CI, 2.1-5.6), renal failure (adjOR, 2.6; 95% CI, 1.5-4.5), ischemic stroke (adjOR, 2.4; 95% CI, 1.2-5.0), platelet (PLT) transfusions (adjOR, 2.2; 95% CI, 1.2-4.1), and myocardial infarction (adjOR, 2.3; 95% CI, 1.2-4.6) were significant independent predictors of mortality in TTP patients who underwent TPE. A prognostic weighted mortality prediction scoring system incorporating arterial thrombosis, intracranial hemorrhage, age, renal failure, ischemic stroke, PLT transfusion, and myocardial infarction showed very good discrimination and was predictive of 78.6% deaths. CONCLUSIONS: Early and targeted therapy for high-risk individuals should be used to guide management of TTP patients for improved survival outcomes.
BACKGROUND: Despite proven efficacy and increased availability of therapeutic plasma exchange (TPE), mortality for patients with thrombotic thrombocytopenic purpura (TTP) remains high with a limited understanding of those at highest risk of death. STUDY DESIGN AND METHODS: This study utilized the Nationwide Inpatient Sample (2007-2012) to derive a prognostic score for mortality in hospitalized TTP patients. Odds ratios of death with various putative risk factors adjusted for age, sex, and race were calculated (adjOR). Weighted mean of adjOR estimates were incorporated in a risk-stratified score. RESULTS: Among 8203 hospitalizations with TTP as primary admission diagnosis who underwent TPE, 613 deaths were identified (all-cause mortality, 7.5%; median time-to-death, 9 days; interquartile range, 4-14 days). In multivariable logistic regression, arterial thrombosis (adjOR 6.7, 95% confidence interval [CI], 1.1-40.9), intracranial hemorrhage (adjOR, 6.1; 95% CI, 1.6-23.2), age at least 60 years (adjOR, 3.5; 95% CI, 2.1-5.6), renal failure (adjOR, 2.6; 95% CI, 1.5-4.5), ischemic stroke (adjOR, 2.4; 95% CI, 1.2-5.0), platelet (PLT) transfusions (adjOR, 2.2; 95% CI, 1.2-4.1), and myocardial infarction (adjOR, 2.3; 95% CI, 1.2-4.6) were significant independent predictors of mortality in TTP patients who underwent TPE. A prognostic weighted mortality prediction scoring system incorporating arterial thrombosis, intracranial hemorrhage, age, renal failure, ischemic stroke, PLT transfusion, and myocardial infarction showed very good discrimination and was predictive of 78.6% deaths. CONCLUSIONS: Early and targeted therapy for high-risk individuals should be used to guide management of TTP patients for improved survival outcomes.
Authors: Nivas Balasubramaniyam; Dhaval Kolte; Chandrasekar Palaniswamy; Kiran Yalamanchili; Wilbert S Aronow; John A McClung; Sahil Khera; Sachin Sule; Stephen J Peterson; William H Frishman Journal: Am J Med Date: 2013-08-29 Impact factor: 4.965
Authors: Ruchika Goel; Paul M Ness; Clifford M Takemoto; Lakshmanan Krishnamurti; Karen E King; Aaron A R Tobian Journal: Blood Date: 2015-01-14 Impact factor: 22.113
Authors: G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff Journal: N Engl J Med Date: 1991-08-08 Impact factor: 91.245
Authors: Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George Journal: Blood Date: 2013-07-09 Impact factor: 22.113
Authors: J N George; S K Vesely; D R Terrell; C C Deford; J A Reese; Z L Al-Nouri; L M Stewart; K H Lu; D S Muthurajah Journal: Hamostaseologie Date: 2013-01-31 Impact factor: 1.778
Authors: Ravi Sarode; Nick Bandarenko; Mark E Brecher; Joseph E Kiss; Marisa B Marques; Zbigniew M Szczepiorkowski; Jeffrey L Winters Journal: J Clin Apher Date: 2013-10-17 Impact factor: 2.821
Authors: X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi Journal: J Thromb Haemost Date: 2020-09-11 Impact factor: 5.824
Authors: Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw Journal: Intensive Care Med Date: 2019-10-07 Impact factor: 17.440
Authors: Flora Peyvandi; Spero Cataland; Marie Scully; Paul Coppo; Paul Knoebl; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Jessica Minkue Mi Edou; Hilde De Winter; Filip Callewaert Journal: Blood Adv Date: 2021-04-27
Authors: Wolfgang Miesbach; Jan Menne; Martin Bommer; Ulf Schönermarck; Thorsten Feldkamp; Martin Nitschke; Timm H Westhoff; Felix S Seibert; Rainer Woitas; Rui Sousa; Michael Wolf; Stefan Walzer; Björn Schwander Journal: Orphanet J Rare Dis Date: 2019-11-15 Impact factor: 4.123
Authors: Murtadha Al-Khabori; Faisal Alsayegh; Hasan Al Yaseen; Sabir Hussien; Amar Lal; Muna Al Rasheed; Mohammad Al Bader; Salam Al Kindi; Mahmoud Marashi Journal: Oman Med J Date: 2022-07-31